Diclofenac toxicity in human intestine ex vivo is not related to the formation of intestinal metabolites.
The use of diclofenac (DCF), a nonsteroidal anti-inflammatory drug, is associated with a high prevalence of gastrointestinal side effects. In vivo studies in rodents suggested that reactive metabolites of DCF produced by the liver or the intestine might be responsible for this toxicity. In the present study, precision-cut intestinal slices (PCIS) prepared from the jejunum of 18 human donors were used as an ex vivo model to investigate whether DCF intestinal metabolites are responsible for its intestinal toxicity in man. PCIS were incubated with a concentration range of DCF (0-600 µM) up to 24 h. DCF (≥400 µM) caused direct toxicity to the intestine as demonstrated by ATP depletion, morphological damage, caspase 3 activation, and lactate dehydrogenase leakage. Three main metabolites produced by PCIS (4'-hydroxy DCF, 5-hydroxy DCF, and DCF acyl glucuronide) were detected by HPLC. Protein adducts were detected by immunohistochemical staining and showed correlation with the intestinal metabolites. DCF induced similar toxicity to each of the samples regardless of the variation in metabolism among them. Less metabolites were produced by slices incubated with 400 µM DCF than with 100 µM DCF. The addition of the metabolic inhibitors such as ketoconazole, cimetidine, or borneol decreased the metabolite formation but increased the toxicity. The results suggest that DCF can induce intestinal toxicity in human PCIS directly at therapeutically relevant concentrations, independent of the reactive metabolites 4'-OH DCF, 5-OH DCF, or diclofenac acylglucuronide produced by the liver or formed in the intestine.
Division of Pharmacokinetics, Toxicology and Targeting, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands, x.niu@rug.nl.
Xiaoyu
X
Niu
Inge A M
IA
de Graaf
Miriam
M
Langelaar-Makkinje
Peter
P
Horvatovich
Geny M M
GM
Groothuis
D000255:Adenosine Triphosphate / Q000378:metabolism; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000378:metabolism / Q000633:toxicity*; D053148:Caspase 3 / Q000378:metabolism; D004008:Diclofenac / Q000031:analogs & derivatives* / Q000378:metabolism / Q000633:toxicity; D005260:Female; D020719:Glucuronides / Q000378:metabolism / Q000633:toxicity*; D006801:Humans; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D007583:Jejunum / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D008875:Middle Aged
C487366:1-O-(2-((2',6'-dichlorophenyl)amino)phenylacetyl)glucopyranuronic acid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D020719:Glucuronides; D004008:Diclofenac; D000255:Adenosine Triphosphate; D007770:L-Lactate Dehydrogenase; D053148:Caspase 3; C117715:5-hydroxydiclofenac; C108036:4'-hydroxydiclofenac